Siponimod not checked

Novartis · BAF312

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
None yet
 
Trials
3 active
9 in total · 3 in the EU
Targets
 

What this is

How it works
Sphingosine 1-phosphate Receptor Modulator FDA class
How it’s given
“Siponimod tablet administered orally once daily. Titration period, Day 1 to Day 6, first dose is either 0.1 mg or 0.25 mg up to daily dose of either 0.5 mg, 1 mg or 2 mg (depending on CYP2C9 genotype and body weight).”In the company’s words, NCT04926818 on ClinicalTrials.gov
Tested for
Multiple Sclerosis (MS)
Main trialPhase 3
“Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis”In the company’s words, NCT04926818 on ClinicalTrials.gov
Other names
BAF312

Other drugs for Multiple Sclerosis (MS)

All 54 drugs for Multiple Sclerosis (MS)

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials9

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 25 Mar 2026 Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis
Phase 4Completed 6 Sep 2021 Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)
Phase 3Completed 29 Apr 2016 Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)
Phase 3Completed 6 Jul 2022 Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients
Phase 2Terminated 17 Feb 2016 Safety and Efficacy of BAF312 in Dermatomyositis
Phase 2Terminated 5 Aug 2016 Efficacy and Tolerability of BAF312 in Patients With Polymyositis
Phase 2Completed 13 May 2020 Efficacy, Safety and Tolerability of BAF312 Compared to Placebo in Patients With Intracerebral Hemorrhage (ICH).
Phase 4Authorised not given Exploring the effect of a novel therapy on chronic intrathecal inflammation in patients with active progressive multiple sclerosis
Phase 4Authorised not given Effect of siponimod on relevant imaging and immunological hallmarks of progressive multiple sclerosis
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Siponimod

Following is part of Solo: you see every change to Siponimod the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in